|Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market|
Home / News
Proceeds of Pharmstandart - 7.755 mlrd rbl.
The proceeds of the Open Society "Pharmstandart" under ISFA in January-September, 2007 have grown up 53% to 7.755mlrd rbl. from 5.08mlrd rbl. in the similar period of the last year. It is spoken about in the report of the company.
Growth under the pro-form (including results of the Joint-Stock Company "Masterlek" since January, 1st, 2006) has made 31%, or 7.756mlrd rbl. against 5.93mlrd rbl.
Pharmstandart - the Russian pharmaceutical company based in 2003. Its structure includes: Pharmstandart -Leksredstva (Kursk), Pharmstandart -Tomskkhimpharm (Tomsk), Pharmstandart -Ufavita (Ufa), Pharmstandart -Fitopharm-NN (Nizhniy Novgorod), the Tyumen factory of medical equipment and tools. Production of the company includes both non-prescription, and prescription medicines. In August, 2006 Pharmstandart has got the company "Masterlek" with its portfolio of brands.
The authorized capital of the company for the end of the last year made 37.8mln rbl. and was divided into 37792603 ordinary shares by face value of 1 rbl. The basic shareholders of Pharmstandart are Augment Investments Limited, registered on Cyprus which in turn belongs to the head of the Board of Pharmstandart Victor Kharitonin, Evgeniy Kulkov, Roman Abramovich, Evgeniy Shvidler and Millhouse Capital Management.
In May 2007 Pharmstandart during IPO has sold 43% of shares and GDR to international and Russian institutional investors.
The net profit of Pharmstandart in the I half-year 2007 under ISFA has grown up 49% to 962mln rbl. in comparison with the similar parameter of the last year. The proceeds from realization of production have grown up 52% to 4.4mlrd rbl.